ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Asahi Gets Judgment In Actelion Lawsuit

by Ann M. Thayer
August 29, 2011 | APPEARED IN VOLUME 89, ISSUE 35

A superior court in California has entered a judgment requiring Switzerland’s Actelion to pay $517 million to Asahi Kasei for breaching a licensing agreement. In May, a jury awarded Asahi $576 million, a portion of which was offset by an arbitration-related payment Actelion made in 2009. The case dates back to 2006 when California-based CoTherix agreed to develop fasudil, a rho-kinase inhibitor discovered by Asahi Kasei Pharma. Actelion acquired CoTherix in early 2007. After development of the drug was discontinued later that year, Asahi sued Actelion for breach of contract. Actelion has been waiting for the judgment to be entered before filing an appeal.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment